REGN · NASDAQ
Regeneron Pharmaceuticals (REGN) Stock Price & Fundamentals
Regeneron Pharmaceuticals (REGN) closed at $497.29 on Oct 9, 2026, down 0.09% from the previous close of $497.75.
Share price, past year
1Y +1.36%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $497.29 |
| Sep 30, 2026 | $477.33 |
| Aug 31, 2026 | $491.54 |
| Jul 31, 2026 | $487.13 |
| Jun 30, 2026 | $523.48 |
| May 29, 2026 | $520.75 |
| Apr 30, 2026 | $489.94 |
| Mar 31, 2026 | $530.66 |
| Feb 27, 2026 | $516.00 |
| Jan 30, 2026 | $480.38 |
| Dec 31, 2025 | $483.21 |
| Nov 28, 2025 | $501.26 |
| Oct 31, 2025 | $468.77 |
Key statistics
- Market cap
- $46.95B
- P/E (TTM)
- 11.0
- EPS (TTM)
- $45.41
- Revenue (TTM)
- $15.53B
- Net income (TTM)
- $4.33B
- Shares outstanding
- 94.4M
- Dividend yield
- 0.73%
- 52-week range
- $464.42 – $532.04
Regeneron Pharmaceuticals's market cap is $46.95B, based on a share price of $497.29 and 94.4M shares outstanding as of Sep 30, 2012.
Financials
Regeneron Pharmaceuticals reported revenue of $14.34B for fiscal 2025, up 0.99% from fiscal 2024.
Regeneron Pharmaceuticals earned net income of $4.50B in fiscal 2025, a net margin of 31.4%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $14.34B | +1.0% | $4.50B | 31.4% | $41.48 | — |
| FY2024ended Dec 31, 2024 | $14.20B | +8.3% | $4.41B | 31.1% | $38.34 | — |
| FY2023ended Dec 31, 2023 | $13.12B | +7.8% | $3.95B | 30.1% | $34.77 | — |
| FY2022ended Dec 31, 2022 | $12.17B | −24.3% | $4.34B | 35.6% | $38.22 | — |
| FY2021ended Dec 31, 2021 | $16.07B | +89.1% | $8.08B | 50.3% | $71.97 | — |
| FY2020ended Dec 31, 2020 | $8.50B | +29.6% | $3.51B | 41.4% | $30.52 | — |
| FY2019ended Dec 31, 2019 | $6.56B | +27.4% | $2.12B | 32.3% | $18.46 | — |
| FY2018ended Dec 31, 2018 | $5.15B | −12.4% | $2.44B | 47.5% | $21.29 | — |
| FY2017ended Dec 31, 2017 | $5.87B | +20.8% | $1.20B | 20.4% | $10.34 | — |
| FY2016ended Dec 31, 2016 | $4.86B | — | $895.50M | 18.4% | $7.70 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $4.29B | $1.30B | $12.23 |
| Q1 FY2026ended Mar 31, 2026 | $3.61B | $727.20M | $6.75 |
| Q4 FY2025ended Dec 31, 2025 | $3.88B | $844.60M | — |
| Q3 FY2025ended Sep 30, 2025 | $3.75B | $1.46B | $13.62 |
| Q2 FY2025ended Jun 30, 2025 | $3.68B | $1.39B | $12.81 |
| Q1 FY2025ended Mar 31, 2025 | $3.03B | $808.70M | $7.27 |
| Q4 FY2024ended Dec 31, 2024 | $3.79B | $917.70M | — |
| Q3 FY2024ended Sep 30, 2024 | $3.72B | $1.34B | $11.54 |
Company profile
- Name
- Regeneron Pharmaceuticals, Inc.
- Ticker
- REGN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 777 Old Saw Mill River Road, Tarrytown, NY 10591
- Incorporated in
- NY
- Fiscal year ends
- December
- SEC CIK
- 0000872589
Recent SEC filings
- Oct 6, 2026
- Sep 30, 2026
- Jul 30, 2026
- Jul 30, 2026
- Jul 6, 2026
- Jun 17, 2026
- Apr 29, 2026
- Apr 29, 2026
Frequently asked questions
What is Regeneron Pharmaceuticals's stock price?
Regeneron Pharmaceuticals (REGN) closed at $497.29 on Oct 9, 2026, down 0.09% from the previous close of $497.75.
What is Regeneron Pharmaceuticals's market cap?
Regeneron Pharmaceuticals's market cap is $46.95B, based on a share price of $497.29 and 94.4M shares outstanding as of Sep 30, 2012.
How much revenue does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals reported revenue of $14.34B for fiscal 2025, up 0.99% from fiscal 2024.
What is REGN's P/E ratio?
Regeneron Pharmaceuticals's price-to-earnings ratio is 11.0, based on trailing twelve-month diluted EPS of $45.41.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. Regeneron Pharmaceuticals declared $3.64 per share in dividends over the last four quarters, a yield of 0.73%.
Sources and methodology
Fundamentals come from Regeneron Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures